Skip to main content

Rheumatoid Arthritis

      The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!
      Rheumatology Round-Up with Drs. Kavanaugh & Cush

      The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020.

      RT @RHEUMarampa: Tofa for RA by the grp of Dr. Atul Deodhar:
      >Tofa(56%) vs. pbo(29.4%)-significant improvement in AS

      sheila RHEUMarampa

      4 years 6 months ago
      Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
      A Review of RA Studies at ACR: Dr. Janet Pope

      Dr. Janet Pope reviews #0483, #0187, #1715, #0151 and #1736 presented at the 2020 ACR annual meeting.

      Lifestyle and Risk of RA, Lupus: Dr. Janet Pope

      Dr. Janet Pope reviews abstracts #1198 and #1473 presented at the 2020 ACR annual meeting.

      New ACR RA Guidelines and Practice Changing Abstracts: RA Panel

      Dr. Jonathan Kay leads an international panel on the new ACR RA guidelines and other practice-changing abstracts presented at the 2020 ACR annual meeting. Panelists include Dr.Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes. 

      Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Pa

      Dr. John Cush RheumNow

      4 years 6 months ago
      Dr. Jonathan Kay leads an international panel of rheumatologists to elicit their opinions on key abstracts at #ACR20. Panelists: @drdavidliew, @ejdein1, @MeralElRamahiMD, @RichardPAConway, @RHEUMarampa, and @jeffsparks https://t.co/btZKgwvoSn https://t.co/Okdvx9HuNc
      Cardiovascular Risk on MTX in Rheumatoid Arthritis: Dr. Jonathan Kay

      Dr. Jonathan Kay reviews several studies that look at the cardiovascular risk of methotrexate in people with rheumatoid arthritis. 

      Vaccination with Shingrix: Does it work for patients on JAKi?

      Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.

      Patient Outcomes on Low-Dose Steroids: Dr. Eric Dein

      Dr. Eric Dein reviews abstract #1998 presented at the 2020 ACR annual meeting.

      Mid-Meeting Recap: Rheumatoid Arthritis

      On Saturday, November 7th, Drs. Cush and Kavanaugh discuss rheumatoid arthritis studies presented at ACR 2020 with Dr. Kathryn Dao and Dr. Jonathan Kay.

      RT @Janetbirdope: What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNF

      Janet Pope Janetbirdope

      4 years 6 months ago
      What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNFi & 2 JAKi @RheumNow #ACR20 @CRASCRRheum
      RT @drdavidliew: Low-dose steroids in RA: what's the harm, right?
      (You probably know where I'm going with this)

      ESPOIR

      David Liew drdavidliew

      4 years 6 months ago
      Low-dose steroids in RA: what's the harm, right? (You probably know where I'm going with this) ESPOIR 10y data: total events, and severe infections worse with dose and time (cumulative 8.4g ≡ 5mg/d) No doubt some residual confounding, but real risk! #ACR20 ABST1998 @RheumNow https://t.co/BAQmOR1ped
      RT @Janetbirdope: What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumato

      Janet Pope Janetbirdope

      4 years 6 months ago
      What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
      RT @RichardPAConway: Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in

      Richard Conway RichardPAConway

      4 years 6 months ago
      Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
      ×